Brought to you by 
Octagen starts up on new Factor VIII candidates from Emory
13 Jul 1999
Executive Summary
Octagen Corp., a new biotech starting out with a focus on hemophilia and other clotting disorders, has licensed second-generation recombinant Factor VIII molecules, in preclinical development, from Emory University.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Octagen starts up on new Factor VIII candidates from Emory
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice